FOXP3 and colorectal carcinoma: Using the FOXP3-TSDR demethylation assay, Wieczorek et al.[4] measured the nTreg proportions (DMR) in the peripheral blood of patients with CRC tumors (n = 27) and in that of healthy donors (n = 20); however, no significant difference was found (2.3% vs. 1.4%, p = 0.068).